How imiquimod licenses plasmacytoid dendritic cells to kill tumors

OncoImmunology

Volumn 1, Issue 9, 2012, Pages 1661-1663

  Holcmann, Martin ^a   Drobits, Barbara ^a   Sibilia, Maria ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cancer; CCL2; Imiquimod; pDC; Type I IFN

Indexed keywords

GRANZYME B; IMIQUIMOD; INTERFERON; INTERFERON RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CELL KILLING; CELL MATURATION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; KILLER CELL; NONHUMAN; NOTE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84885819417     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22033     Document Type: Note

References (10)

1. Schön MP, Schön M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008; 27:190-9; PMID:18176600; http://dx.doi.org/10.1038/sj.onc.1210913.
2. Palamara F, Meindl S, Holcmann M, Lührs P, Stingl G, Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004; 173:3051- 61; PMID:15322165.
3. Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, et al. Plasmacytoid dendritic cells induce NK celldependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 2008; 118:1165-75; PMID:18259609.
4. Zitvogel L, Housseau F. IKDCs or B220+ NK cells are pre-mNK cells. Blood 2012; 119:4345-6; PMID:22577157; http://dx.doi.org/10.1182/blood-2012-03-415026.
5. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8- activated inflammatory dendritic cells. J Exp Med 2007; 204:1441-51; PMID:17535975; http://dx.doi.org/10.1084/jem.20070021.
6. Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 2012; 122:575-85; PMID:22251703; http://dx.doi.org/10.1172/JCI61034.
7. Heib V, Becker M, Warger T, Rechtsteiner G, Tertilt C, Klein M, et al. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice. Blood 2007; 110:946-53; PMID:17446350; http://dx.doi.org/10.1182/blood-2006-07-036889.
8. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093.
9. Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, et al. Mechanisms of Interferonalpha induced apoptosis in malignant cells. Oncogene 2002; 21:1251-62; PMID:11850845; http://dx.doi.org/10.1038/sj.onc.1205179.
10. Kalb ML, Glaser A, Stary G, Koszik F, Stingl G. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-a-mediated antitumor reactivity. J Immunol 2012; 188:1583-91; PMID:22231699; http://dx.doi.org/10.4049/jimmunol.1102437.